Investor Presentation Q1 2018 Audited Results

III Key Investment Highlights 5 Resilient Supply Chain Highly diversified supplier/client base significantly mitigating supply chain risks Diversified Geographical Presence NORTH SINAL Alexandria 14.9% Cairo & Canal 30.6% Minimal Supplier Concentration Sanofi Aventis 7% Amoun 5% Novartis 4% Expansive SKUs Coverage Distributed by ISP 93% MATHUH GIZA MINYA SURZ ASSUT SOHAG NEW VALLEY QENA LUXOR SOUTHSINA Minimal operational risk 56 sites with 56 lifetime Upper Egypt 26.0% % of Sales Mina Pharm 3% Glaxo Smith Kline 3% % of Market Sales IN 2000 1250 and abo licenses Delta 28.5% Low client concentration risk due to small number of pharmacy chains in Egypt Cairo & Canal region has the highest sales contribution due to higher purchasing power Others 79% No FX Risk Minimal supplier concentration with the top five supplier representing less than 25% of sales Not Distributed by ISP 7% Product portfolio covers 85% of the SKUs available in the market, collectively representing 93% of the market sales value V NOVARTIS PHARMACEUTICALS Multiple Contracts with Key Suppliers gsk Pfizer AstraZeneca PHARCO PHARMACEUTICALS SERVIER ibnsinapharma MUP Medical Union Pharmaceuticals SEDICO ய سديك SANOFI Abbott Roche MINAPHARM AIKMA Marcyrl QUALITY GNP EIPICO AMOUN EVAPHARMA Securing Your Health Source: IMS Health; Company Management No SKU Concentration (Each SKU ≤0.5% of sales) map Multi-Apex Pharma 16

View entire presentation